Nuria Chic

Research group

Translational genomics and targeted therapies in solid tumours Pre-doctoral researcher (R1)

chic@clinic.cat 0000-0001-9736-6276

Featured publications

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer

Authors:
Chic, N; Luen, SJ; Nuciforo, P; Salgado, R; Fumagalli, D;

(...)

Di Cosimo, S; Saura, C; Huober, J; Prat, A; Loi, S.

Reference: Journal Of The National Cancer Institute 2022.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Authors:
Prat, A; Chaudhury, A; Solovieff, N; Paré, L; Martinez, D;

(...)

Brasó-Maristany, F; Lteif, A; Taran, T; Babbar, N; Su, F.

Reference: Journal Of Clinical Oncology 2021.
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Authors:
Buus, R; Szijgyarto, Z; Schuster, EF; Xiao, H; Haynes, BP;

(...)

Seguí, E; Chic, N; Prat, A; Dowsett, M; Cheang, MCU.

Reference: Npj Breast Cancer 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Authors:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Reference: Npj Breast Cancer 2021.
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Authors:
Guarneri V; Dieci MV; Bisagni G; Brandes AA; Frassoldati A;

(...)

Paré L; Chic N; D'Amico R; Prat A; Conte P .

Reference: Clinical Cancer Research 2020.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Authors:
Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

(...)

Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

Reference: Lancet Oncology 2020.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Authors:
Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;

(...)

Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.

Reference: Breast Cancer Research 2020.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Authors:
Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

(...)

Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

Reference: Cancer Treatment Reviews 2020.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Authors:
Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

(...)

Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

Reference: Nature Communications 2020.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.

Authors:
Díaz-Redondo T; Lavado-Valenzuela R; Jimenez B; Pascual T; Gálvez F;

(...)

Jerez JM; Alvarez M; Prat A; Ribelles N; Alba E .

Reference: Frontiers In Oncology 2019.

Featured Projects

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Funder: Fundació Clínic per la Recerca Biomèdica (Sede o evento)

Duration: 01/02/2020
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Funder: Hospital Clinic de Barcelona (Sede o evento)

Duration: 02/12/2019

Nuria Chic

Research group

Featured publications

Featured Projects

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Subscribe to the Newsletter of Clínic